1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/28920
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBajenaru O.en
dc.contributor.authorBergmann L.en
dc.contributor.authorBourgeois P.en
dc.contributor.authorCubo E.en
dc.contributor.authorDavis T.L.en
dc.contributor.authorIansek R.en
dc.contributor.authorKovacs N.en
dc.contributor.authorKukreja P.en
dc.contributor.authorOnuk K.en
dc.contributor.authorPontieri F.E.en
dc.contributor.authorRobieson W.en
dc.contributor.authorSiddiqui M.S.en
dc.contributor.authorSimu M.en
dc.contributor.authorStandaert D.G.en
dc.contributor.authorRay Chaudhuri K.en
dc.contributor.authorAldred J.en
dc.contributor.authorAnca-Herschkovitsch M.en
dc.contributor.authorAntonini A.en
dc.date.accessioned2021-05-14T09:44:55Zen
dc.date.available2021-05-14T09:44:55Zen
dc.date.copyright2020en
dc.date.created20201121en
dc.date.issued2020-11-21en
dc.identifier.citationNeurodegenerative Disease Management. 10 (5) (pp 309-323), 2020. Date of Publication: October 2020.en
dc.identifier.issn1758-2024en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/28920en
dc.description.abstractAim: A Delphi expert consensus panel proposed that fulfilling >=1 of the a 5-2-1 criteria' (>=five-times daily oral levodopa use, >=two daily hours with a Off' symptoms or >=one daily hour with troublesome dyskinesia) suggests advanced Parkinson's disease (PD). Patients & methods: DUOdopa/Duopa in Patients with Advanced PD-a GLobal OBservational Study Evaluating Long-Term Effectiveness (DUOGLOBE)-is a single-arm, postmarketing, observational, long-term effectiveness study of levodopa-carbidopa intestinal gel (LCIG) for advanced PD. Result(s): This 6-month interim analysis (n = 139) affirms that most (98%) enrolled patients fulfill >=1 of the 5-2-1 criteria. These patients responded favorably to LCIG treatment. Safety was consistent with other LCIG studies. Conclusion(s): In advanced PD patients, the 5-2-1 criteria generally aligns with clinician assessment.Copyright © 2020 AbbVie Inc., employer of authors L Bergmann, P Kukreja, K Onuk, W Robieson.en
dc.languageEnglishen
dc.languageenen
dc.publisherFuture Medicine Ltd.en
dc.relation.ispartofNeurodegenerative Disease Managementen
dc.titleApplication of the a 5-2-1' screening criteria in advanced Parkinson's disease: Interim analysis of DUOGLOBE.en
dc.typeArticleen
dc.type.studyortrialObservational study (cohort, case-control, cross sectional or survey)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.2217/nmt-2020-0021-
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid32873195 [http://www.ncbi.nlm.nih.gov/pubmed/?term=32873195]en
dc.identifier.source633061904en
dc.identifier.institution(Aldred) Selkirk Neurology and Inland Northwest Research, Spokane, 610 S Sherman St #201 and 208, Spokane, WA 99202, United States (Anca-Herschkovitsch) Department of Neurology, Edith Wolfson Medical Center, Tel Aviv University, 62 Ha-Lokhamim St, Holon, Israel (Antonini) Department of Neuroscience, Padua University, Padova, Padua, Veneto 5-35128, Italy (Bajenaru) Department of Neurology, University of Medicine and Pharmacy Carol Davila, Bulevardul Eroii Sanitari 8, Bucharest, Romania (Bergmann, Kukreja, Onuk, Robieson) AbbVie Inc., 1 Waukegan Rd, North Chicago, IL 60064, United States (Bourgeois) Department of Neurology Az Groeninge, President Kennedylaan 4, Kortrijk, Belgium (Cubo) Neurology Department, Hospital Universitario Burgos, Av. Islas Baleares, 3, Burgos, Spain (Davis) Department of Neurology, Vanderbilt University Medical Center, 1211 Medical Center Dr, Nashville, TN 37232, United States (Iansek) Kingston Centre, Monash Health, 400 Warrigal Rd, Melbourne, VIC, Australia (Kovacs) Department of Neurology, University of Pecs, 48-as ter 1, Pecs, Hungary (Pontieri) Department of Neurological Sciences, Sapienza University of Rome, Piazzale Aldo Moro, 5, Rome, Italy (Siddiqui) Department of Neurology, Wake Forest School of Medicine, 475 Vine St, Winston Salem, NC 27101, United States (Simu) Department of Neurology, Victor Babes University of Medicine and Pharmacy, Piata Eftimie Murgu 2, Timisoara, Romania (Standaert) Department of Neurology, University of Alabama at Birmingham, 1720 University Blvd, Birmingham, AL 35294, United States (Ray Chaudhuri) Parkinson Foundation International Centre of Excellence, King's College and King's College Hospital, Denmark Hill, London, United Kingdomen
dc.description.addressJ. Aldred, Selkirk Neurology and Inland Northwest Research, Spokane, 610 S Sherman St #201 and 208, Spokane, WA 99202, United States. E-mail: jaldred@selkirkneurology.comen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2020 Elsevier B.V., All rights reserved.en
dc.subect.keywords5-2-1 criteria for advanced PD dyskinesia LCIG levodopa levodopa-carbidopa intestinal gel off time Parkinson's diseaseen
dc.identifier.authoremailAldred J.; jaldred@selkirkneurology.comen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeArticle-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
crisitem.author.deptNeurology-
crisitem.author.deptMonash Ageing Research Centre (MONARC)-
Appears in Collections:Articles
Show simple item record

Page view(s)

28
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.